Injectable RANKL sustained release formulations to accelerate orthodontic tooth movement
Open Access
- 23 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Orthodontics
- Vol. 42 (3) , 317-325
Abstract
Accelerating orthodontic tooth movement (OTM) through biologically effective methods, such as increasing osteoclast-mediated alveolar resorption, could effectively shorten treatment time. To evaluate an injectable formulation containing receptor activator of nuclear factor kappa-B ligand (RANKL) on the OTM. We fabricated a RANKL formulation from 100 µl of 100 µg/ml RANKL adsorbed on 10 mg of poly(lactic acid-co-glycolic acid) microspheres embedded in a 10 wt% aqueous hydroxyethyl cellulose carrier gel. We characterized these formulations for the rate of RANKL release, and then tested for bioactivity using in vitro cell culture. In vivo OTM studies were conducted using 15 week old male Wistar rats for 14 days. We injected the RANKL formulations palatal to the left maxillary first molar and accomplished OTM with a nickel–titanium (NiTi) coil spring applying 5–8 g force. Control groups involved the application of NiTi coil spring with and without placebo formulation. The outcome measure included the distance of tooth movement, bone volume fraction, tissue density, and root volume determined with micro-computed tomography. We determined the amount of osteoclast activity using tartrate-resistant acid phosphatase (TRAP) staining. These formulations were able to sustain the release of RANKL for more than 30 days, and the released RANKL showed a positive effect on mice osteoclast precursor cells (RAW 264.7). Reported injectable RANKL formulations were effective in accelerating OTM compared with other control groups, with 129.2 per cent more tooth movement than no formulation and 71.8 per cent more than placebo formulation, corresponding with a significant increase in the amount of TRAP activity. We did not observe any significant differences in root resorption between the groups. Our study shows a significant increase in OTM with injectable formulations containing RANKL.Keywords
Funding Information
- American Association of Orthodontists Foundation
- National Institutes of Health (NIH RO1EB020640, KO8DEO25914)
This publication has 45 references indexed in Scilit:
- RANKL delivery from calcium phosphate containing PLGA microspheresJournal of Biomedical Materials Research Part A, 2013
- The use of gene therapy vs. corticotomy surgery in accelerating orthodontic tooth movementOrthodontics & Craniofacial Research, 2011
- RANK/RANKL/OPG during orthodontic tooth movementOrthodontics & Craniofacial Research, 2009
- Design and release characteristics of sustained release tablet containing metformin HClRevista Brasileira de Ciências Farmacêuticas, 2008
- Levels of RANKL and OPG in gingival crevicular fluid during orthodontic tooth movement and effect of compression force on releases from periodontal ligament cells in vitroOrthodontics & Craniofacial Research, 2006
- Local RANKL gene transfer to the periodontal tissue accelerates orthodontic tooth movementGene Therapy, 2006
- Synthesis and characterization of modified chitosan microspheres: Effect of the grafting ratio on the controlled release of nifedipine through microspheresJournal of Applied Polymer Science, 2003
- Synthesis and characterization of polyacrylamide‐grafted chitosan hydrogel microspheres for the controlled release of indomethacinJournal of Applied Polymer Science, 2002
- TGF-β Enhances Osteoclast Differentiation in Hematopoietic Cell Cultures Stimulated with RANKL and M-CSFBiochemical and Biophysical Research Communications, 1999
- Bicontinuous Controlled-Release Matrices Composed of Poly(D,L-lactic acid) Blended with Ethylene—Vinyl Acetate Copolymer1991